Shopping Cart 0
Cart Subtotal
USD 0

Middle East Respiratory Syndrome (MERS)-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Middle East Respiratory Syndrome (MERS)-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Middle East Respiratory Syndrome (MERS)-Pipeline Review, H2 2017, provides an overview of the Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline landscape.

Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV). Symptoms include fever, cough and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. Pneumonia is common, and sometimes it cause injury to organs, such as the kidneys. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Middle East Respiratory Syndrome (MERS)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (MERS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Middle East Respiratory Syndrome (MERS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 8 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Middle East Respiratory Syndrome (MERS) (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Middle East Respiratory Syndrome (MERS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Middle East Respiratory Syndrome (MERS) (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Middle East Respiratory Syndrome (MERS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Middle East Respiratory Syndrome (MERS) (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Middle East Respiratory Syndrome (MERS) (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Middle East Respiratory Syndrome (MERS)-Overview

Middle East Respiratory Syndrome (MERS)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Middle East Respiratory Syndrome (MERS)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Middle East Respiratory Syndrome (MERS)-Companies Involved in Therapeutics Development

Autoimmune Technologies LLC

Gilead Sciences Inc

Inovio Pharmaceuticals Inc

NanoViricides Inc

Novavax Inc

Phelix Therapeutics LLC

Regeneron Pharmaceuticals Inc

Romark Laboratories LC

Middle East Respiratory Syndrome (MERS)-Drug Profiles

3B-11-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNSP-333S1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSW-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Middle East Respiratory Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Inhibit Cathepsin L for Coronaviridae Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-2101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-5734-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-4500-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LCA-60-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Middle East respiratory syndrome coronavirus vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Middle East respiratory syndrome coronavirus vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Middle East respiratory syndrome vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Middle East respiratory syndrome vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nitazoxanide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-3048-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-3051-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAB-301-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Middle East Respiratory Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Middle East Respiratory Syndrome (MERS)-Dormant Projects

Middle East Respiratory Syndrome (MERS)-Product Development Milestones

Featured News & Press Releases

Sep 18, 2017: Inovio and Partners Initiate Phase 1/2a Clinical Trial To Further Advance Its Vaccine Against Deadly MERS Infection

Feb 23, 2017: Inovio Reports New Positive Clinical Data on MERS Vaccine GLS-5300

Dec 06, 2016: Inovio MERS Vaccine Development to be Expanded with Funding from International Vaccine Institute

Aug 24, 2016: SAB Biotherapeutics Announces Contract with BARDA to Advance First MERS Treatment

Aug 11, 2016: Phase I Clinical Trials Underway for First MERS Treatment

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Middle East Respiratory Syndrome (MERS), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Middle East Respiratory Syndrome (MERS), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Middle East Respiratory Syndrome (MERS)-Pipeline by Autoimmune Technologies LLC, H2 2017

Middle East Respiratory Syndrome (MERS)-Pipeline by Gilead Sciences Inc, H2 2017

Middle East Respiratory Syndrome (MERS)-Pipeline by Inovio Pharmaceuticals Inc, H2 2017

Middle East Respiratory Syndrome (MERS)-Pipeline by NanoViricides Inc, H2 2017

Middle East Respiratory Syndrome (MERS)-Pipeline by Novavax Inc, H2 2017

Middle East Respiratory Syndrome (MERS)-Pipeline by Phelix Therapeutics LLC, H2 2017

Middle East Respiratory Syndrome (MERS)-Pipeline by Regeneron Pharmaceuticals Inc, H2 2017

Middle East Respiratory Syndrome (MERS)-Pipeline by Romark Laboratories LC, H2 2017

Middle East Respiratory Syndrome (MERS)-Dormant Projects, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Autoimmune Technologies LLC

Gilead Sciences Inc

Inovio Pharmaceuticals Inc

NanoViricides Inc

Novavax Inc

Phelix Therapeutics LLC

Regeneron Pharmaceuticals Inc

Romark Laboratories LC